Contact Us
Drug Search Results
More Filters [+]

BD-111

Alternative Names: bd-111, bd 111, bd111
Latest Update: 2024-06-27
Latest Update Note: Clinical Trial Update

Product Description

BD111 is a novel gene editing product designed to clear Herpes simplex virus type I (HSV-1) that results in herpetic stromal keratitis in both acute and recurrent infection models which is the leading factor for infectious blindness. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04560790)

Mechanisms of Action: Gene Therapy,HSV

Novel Mechanism: Yes

Modality: Gene Therapy

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shanghai Bdgene
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BD-111

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Herpes Simplex|Keratitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
BD-HSK-111002-Ⅱa

P2

Not yet recruiting

Keratitis|Herpes Simplex

2025-12-01

BD-HSK-111002-Ⅰ

P1

Recruiting

Keratitis|Herpes Simplex

2025-09-01

Recent News Events

Date

Type

Title

05/24/2024

News Article

 Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®

01/12/2022

News Article

 CRISPR Gene Editing Market, 2031 - ResearchAndMarkets.com

01/12/2022

News Article

 Global $18.85 Bn CRISPR Gene Editing Markets to 2031 - Focus on gRNA Design & Vector Construction, Cell Line and Engineering, Screening Services, and Other Services

09/09/2021

News Article

 CRISPR Based Therapeutics Market, 2030

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions